Description:
Insulin-like growth factor-I (IGF-I) acts as an important mediator between growth hormone and growth throughout fetal and childhood development. More circumstantial evidence indicates the association of IGF-I to the risk of cancer. High concentrations of IGF-I has been shown to be an increased risk of colorectal cancer and breast cancer in some studies and less consistently with prostate, thyroid, and haematological malignancies. IGF-I is a potent mitogen and important stimulus for adipocyte differentiation. IGF-I can reduce hyperglycemia in patients with severe insulin resistance by direct effects mediated via the IGF-I receptor. IGF-I infusion lowers insulin and lipid levels in healthy humans and reduces plasma leptin concentrations in rats, suggesting that IGF-I may reduce the degree of insulin resistance in type 2 diabetes, obesity, and hyperlipidemia.Principle:
Mouse Cytokine ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes rabbit anti-mouse antibodies for immobilization on the microtiter wells and rabbit anti-mouse antibodies along with streptavidin conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two antibodies, resulting in the molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of VEGF is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.
Data:
